Protein microarray serological data

Background corrected and normalised microarray median florescence intensity data, for all individuals in the study (n=648). Data from IVTT protein targets are presented along with control targets in tab 1 and 2 (n=762). Data from the gametocyte IVTT protein targets only are presented in tab 3 (n=528)

Metadata for the protein micro-array serological analysis

Metadata for the protein microarray serological analysis. Full description of the variables provided is in tab 2 (key)

Additional file 4 of Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data

Additional file 4: Table S13. Risk of bias assessment. Table S14. Individual participant data not available. Fig. S12. Sensitivity analysis for the main haematological results

Additional file 3 of Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data

Additional file 3: Table S2. Baseline characteristics of patients in the analysis of haematological response. Table S3. Association between haemoglobin change and baseline value. Table S4. Bi-variable analysis of factors associated with drop in haemoglobin on Day 7. Table S5. Bi-variable analysis of factors associated with anaemia on Day 7. Table S6. Univariable analysis of recovery from anaemia. Table S7. Haemoglobin measurements in patients with severe anaemia at any time. Table S8. Baseline characteristics of patients included in the analysis of adverse events. Table S9. Listing of Serious Adverse Events reported in any study. Table S10. Baseline characteristics of patients included in the analysis of haemoglobinuria. Table S11. Univariable analysis for haemoglobinuria. Table S12. Multivariable model of change in haemoglobin on Day 7 in sub-Saharan Africa. Fig. S1. Map of study sites. Fig. S2. Haemoglobin in G6PD deficient patients not included in the Day 7 analysis. Fig. S3. Relationship between haemoglobin at baseline and Day 7 as absolute change. Fig. S4. Relationship between haemoglobin at baseline and Day 7 as fractional change Fig. S5. Relationship between baseline parasitaemia and haematological endpoints. Fig. S6. Dose response relationship for haematological endpoints. Fig. S7. Time to recovery by day when anaemia was first recorded. Fig. S8. Meta-analysis of odds of haemoglobinuria after PQ administration. Fig. S9. Distribution of parasitaemia (observed) used in the simulation study. Figure S10- Predicted risk of severe anaemia (Hb<7g/dL) on Day 7. Fig. S11. Predicted risk of very severe anaemia (Hb<5g/dL) on Day 7

Additional file 2 of Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data

Additional file 2: List L1. List of included studies. Table S1. Summary of characteristics of included studies

Additional file 1 of Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data

Additional file 1:. Details of Methodology